1
|
Westerhout EM, Hamdi M, Stroeken P, Nowakowska NE, Lakeman A, van Arkel J, Hasselt NE, Blejlevens B, Akogul N, Haneveld F, Chan A, van Sluis P, Zwijnenburg D, Volckmann R, van Noesel CJ, Adameyko I, van Gronigen T, Koster J, Valentijn LJ, van Nes J, Versteeg R. Correction: Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors. Cancer Res 2022; 82:2657. [PMID: 35844173 DOI: 10.1158/0008-5472.can-22-1915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Westerhout EM, Hamdi M, Stroeken P, Nowakowska NE, Lakeman A, van Arkel J, Hasselt NE, Bleijlevens B, Akogul N, Haneveld F, Chan A, van Sluis P, Zwijnenburg D, Volckmann R, van Noesel CJ, Adameyko I, van Groningen T, Koster J, Valentijn LJ, van Nes J, Versteeg R. Mesenchymal type neuroblastoma cells escape ALK inhibitors. Cancer Res 2021; 82:484-496. [PMID: 34853072 DOI: 10.1158/0008-5472.can-21-1621] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 09/08/2021] [Accepted: 11/23/2021] [Indexed: 11/16/2022]
Abstract
Cancer therapy frequently fails due to the emergence of resistance. Many tumors include phenotypically immature tumor cells, which have been implicated in therapy resistance. Neuroblastoma cells can adopt a lineage committed adrenergic (ADRN) or an immature mesenchymal (MES) state. They differ in epigenetic landscape and transcription factors, and MES cells are more resistant to chemotherapy. Here we analyzed the response of MES cells to targeted drugs. Activating ALK mutations are frequently found in neuroblastoma and ALK inhibitors (ALKi) are in clinical trials. ALKi treatment of ADRN neuroblastoma cells with a tumor-driving ALK mutation induced cell death. Conversely, MES cells did not express either mutant or wild-type ALK and were resistant to ALKi, and MES cells formed tumors that progressed under ALKi therapy. In assessing the role of MES cells in relapse development, TRAIL was identified to specifically induce apoptosis in MES cells and suppress MES tumor growth. Addition of TRAIL to ALKi treatment of neuroblastoma xenografts delayed relapses in a subset of the animals, suggesting a role for MES cells in relapse formation. While ADRN cells resembled normal embryonal neuroblasts, MES cells resembled immature precursor cells which also lacked ALK expression. Resistance to targeted drugs can therefore be an intrinsic property of immature cancer cells based on their resemblance to developmental precursors.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Boris Bleijlevens
- Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam
| | | | | | | | | | | | | | | | | | | | - Jan Koster
- Department of Oncogenomics, Amsterdam UMC, University of Amsterdam
| | | | | | | |
Collapse
|
3
|
van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet 2017. [PMID: 28650485 DOI: 10.1038/ng.3899] [Citation(s) in RCA: 290] [Impact Index Per Article: 41.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Neuroblastoma and other pediatric tumors show a paucity of gene mutations, which has sparked an interest in their epigenetic regulation. Several tumor types include phenotypically divergent cells, resembling cells from different lineage development stages. It has been proposed that super-enhancer-associated transcription factor (TF) networks underlie lineage identity, but the role of these enhancers in intratumoral heterogeneity is unknown. Here we show that most neuroblastomas include two types of tumor cells with divergent gene expression profiles. Undifferentiated mesenchymal cells and committed adrenergic cells can interconvert and resemble cells from different lineage differentiation stages. ChIP-seq analysis of isogenic pairs of mesenchymal and adrenergic cells identified a distinct super-enhancer landscape and super-enhancer-associated TF network for each cell type. Expression of the mesenchymal TF PRRX1 could reprogram the super-enhancer and mRNA landscapes of adrenergic cells toward a mesenchymal state. Mesenchymal cells were more chemoresistant in vitro and were enriched in post-therapy and relapse tumors. Two super-enhancer-associated TF networks, which probably mediate lineage control in normal development, thus dominate epigenetic control of neuroblastoma and shape intratumoral heterogeneity.
Collapse
Affiliation(s)
- Tim van Groningen
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Jan Koster
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Linda J Valentijn
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Danny A Zwijnenburg
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Nurdan Akogul
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Nancy E Hasselt
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Marloes Broekmans
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Franciska Haneveld
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | | | - Johannes Bras
- Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands
| | | | - Aldo Jongejan
- Department of Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands
| | - Antoine H van Kampen
- Department of Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands
| | - Linda Koster
- Department of Genome Diagnostics, Academic Medical Center, Amsterdam, the Netherlands
| | - Frank Baas
- Department of Genome Diagnostics, Academic Medical Center, Amsterdam, the Netherlands
| | | | | | - Maria C Lecca
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Alvin Chan
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Arjan Lakeman
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Piet Molenaar
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Richard Volckmann
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Ellen M Westerhout
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Mohamed Hamdi
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Peter G van Sluis
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Marli E Ebus
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Jan J Molenaar
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Godelieve A Tytgat
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands
| | - Bart A Westerman
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Johan van Nes
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands
| | - Rogier Versteeg
- Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.,Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands
| |
Collapse
|